Quality of Life After Bladder Cancer (Q-ABC): A comparison of patient related outcomes following radical surgery or radiotherapy
Chief Investigator: Dr Ashok Nikapota
Principal Investigator (Clinical): Dr Sally Appleyard
Principal Investigator for Quality of Life (QoL) Data: Dr Susan Catt
Data Manager for Quality of Life: Shirley May
QoL Coordinator: TBC
FUNDED BY: Roche & Varian
Radical surgery has been considered to be the standard of care for patients with muscle invasive bladder cancer, but:-
- two recent RCTs have shown radiotherapy with either concurrent chemotherapy or nicotinamide and carbogen are at least as successful (in terms of overall survival) as historical series of patients treated with surgery
- a large retrospective study in Leeds (n=458) between 1993 & 1996 found no difference in survival between patients treated with radiotherapy or surgery – with 10 year follow-up data
- NICE guidelines acknowledge there is little evidence that one treatment is more effective than the other recommending patients are offered a choice of radical surgery or radiotherapy with a radio-sensitizer
- the only randomised trial (SPARE) that attempted a head to head evaluation of surgical outcomes with radical radiotherapy closed early due to poor recruitment and the possibility of another RCT is remote
The aim of the Q-ABC study is to address the current paucity of information available to patients and clinicians facing treatment decisions where increasingly evidence is showing surgery and radiotherapy can provide equivalent overall survival.
Publication: Quality of Life after Bladder Cancer: A Prospective Study Comparing Patient-related Outcomes after Radical Surgery or Radical Radiotherapy for Bladder Cancer. Nikapota AD, Cresswell J, Appleyard S, Catt SL. Clin Oncol (R Coll Radiol). 2016 Jun;28(6):373-5.